A detailed history of Nuveen Asset Management, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 101,422 shares of AXSM stock, worth $9.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101,422
Previous 102,645 1.19%
Holding current value
$9.45 Million
Previous $8.26 Million 10.29%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.93 - $95.84 $96,531 - $117,212
-1,223 Reduced 1.19%
101,422 $9.11 Million
Q2 2024

Aug 09, 2024

SELL
$65.72 - $80.5 $9.39 Million - $11.5 Million
-142,882 Reduced 58.19%
102,645 $8.26 Million
Q1 2024

May 13, 2024

BUY
$69.39 - $97.64 $755,032 - $1.06 Million
10,881 Added 4.64%
245,527 $19.6 Million
Q4 2023

Feb 14, 2024

BUY
$57.42 - $83.61 $1.04 Million - $1.51 Million
18,089 Added 8.35%
234,646 $18.7 Million
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $7.99 Million - $9.48 Million
115,342 Added 113.96%
216,557 $15.1 Million
Q2 2023

Aug 14, 2023

SELL
$58.41 - $90.35 $777,261 - $1.2 Million
-13,307 Reduced 11.62%
101,215 $7.27 Million
Q1 2023

May 15, 2023

SELL
$58.39 - $75.0 $433,428 - $556,725
-7,423 Reduced 6.09%
114,522 $7.06 Million
Q4 2022

Feb 14, 2023

SELL
$39.94 - $79.72 $22.8 Million - $45.6 Million
-571,579 Reduced 82.42%
121,945 $9.41 Million
Q3 2022

Nov 14, 2022

SELL
$36.06 - $69.85 $2.79 Million - $5.41 Million
-77,473 Reduced 10.05%
693,524 $30.9 Million
Q2 2022

Aug 15, 2022

BUY
$21.74 - $46.75 $7.57 Million - $16.3 Million
348,317 Added 82.41%
770,997 $29.5 Million
Q1 2022

May 16, 2022

SELL
$23.7 - $41.39 $1.7 Million - $2.96 Million
-71,526 Reduced 14.47%
422,680 $14.1 Million
Q4 2021

Feb 14, 2022

BUY
$30.7 - $43.36 $90,534 - $127,868
2,949 Added 0.6%
494,206 $18.7 Million
Q3 2021

Nov 12, 2021

SELL
$19.91 - $68.26 $3.33 Million - $11.4 Million
-167,077 Reduced 25.38%
491,257 $14.6 Million
Q2 2021

Aug 16, 2021

BUY
$50.63 - $73.5 $8.08 Million - $11.7 Million
159,584 Added 32.0%
658,334 $44.4 Million
Q1 2021

May 17, 2021

SELL
$55.91 - $81.44 $471,489 - $686,783
-8,433 Reduced 1.66%
498,750 $28.2 Million
Q4 2020

May 17, 2021

SELL
$66.31 - $86.52 $465,230 - $607,024
-7,016 Reduced 1.36%
507,183 $41.3 Million
Q4 2020

Feb 16, 2021

SELL
$66.31 - $86.52 $1.15 Million - $1.5 Million
-17,356 Reduced 3.27%
514,199 $41.9 Million
Q3 2020

Nov 16, 2020

BUY
$68.34 - $85.84 $21.5 Million - $27 Million
314,466 Added 144.86%
531,555 $37.9 Million
Q2 2020

Aug 14, 2020

BUY
$49.87 - $98.69 $1.79 Million - $3.54 Million
35,913 Added 19.82%
217,089 $17.9 Million
Q1 2020

May 14, 2020

BUY
$41.2 - $101.31 $3.3 Million - $8.1 Million
80,000 Added 79.07%
181,176 $10.7 Million
Q4 2019

Feb 14, 2020

SELL
$16.71 - $106.24 $39,819 - $253,169
-2,383 Reduced 2.3%
101,176 $10.5 Million
Q3 2019

Nov 14, 2019

BUY
$20.24 - $29.16 $118,140 - $170,206
5,837 Added 5.97%
103,559 $2.1 Million
Q2 2019

Aug 15, 2019

BUY
$13.46 - $25.75 $1.32 Million - $2.52 Million
97,722 New
97,722 $2.52 Million

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.99B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.